Europe Active Pharmaceutical Ingredients (API) Market, By Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS and Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application) – Industry Trends and Forecast to 2030.
Europe Active Pharmaceutical Ingredients (API) Market Analysis and Size
The number of elderly people worldwide is growing. The UN projects that by 2050, there will be 2.1 billion people in the world who are 65 years of age or older, up from 962 million in 2018. The immune system becomes less effective as people age, making them more vulnerable to contracting infectious diseases. Thus, this will boost the market growth.
Data Bridge Market Research analyses that the active pharmaceutical ingredients (API) market which is USD 56.75 billion in 2022, is expected to reach USD 105.20 billion by 2030, at a CAGR of 8.02% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Active Pharmaceutical Ingredients (API) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Molecule (Small Molecule, Large Molecule), Type (Innovative Active Pharmaceutical Ingredients, Generic Innovative Active Pharmaceutical Ingredients), Type of Manufacturer (Captive API Manufacturer, Merchant API Manufacturer), Synthesis (Synthetic Active Pharmaceutical Ingredients and Biotech Active Pharmaceutical Ingredients), Chemical Synthesis (Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, Others), Type of Drug (Prescription Drugs, Over-the-Counter), Usage (Clinical, Research), Potency (Low-to-Moderate Potency Active Pharmaceutical Ingredients, Potent-to-Highly Potent Active Pharmaceutical Ingredient), Therapeutic Application (Cardiology, CNS and Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Therapeutic Application)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), UCB S.A. (Belgium), Sunovion Pharmaceuticals Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.), AstraZeneca (U.K.), GSK plc (U.K.), H. Lundbeck A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Cadila Pharmaceuticals (India)
|
|
Market Opportunities
|
|
Market Definition
The component of a prescription or over-the-counter (OTC) drug that has the desired medical effects is known as an active pharmaceutical ingredient (API). If a prescription drug is available as a generic, both its name and API are the same. Multiple active ingredients that may act differently or treat various symptoms make up combination therapy.
Europe Active Pharmaceutical Ingredients (API) Market Dynamics
Drivers
- Rising Incidence of Chronic Diseases
The rising prevalence of chronic diseases fuels the market. According to the International Diabetes Federation, approximately 463 million people worldwide were diagnosed with diabetes in 2019. Furthermore, the annual number of new cancer cases is expected to reach 23.6 million by 2030. Aside from cancer, many other diseases have seen an increase in prevalence. As a result of the growing number of chronic disease cases, the market's demand and growth increase.
- Growing Approvals from ANDA
The increasing number of Abbreviated New Drug Applications (ANDA) approvals raises the demand for active pharmaceutical ingredients (API). To market a generic drug, a company must file an Abbreviated New Drug Application (ANDA). ANDA approval indicates that the generic drug is similar to the original drug in terms of dosage form, route of administration, strength, quality, performance characteristics, and intended use. As a result, these approvals aid in the faster adoption of APIs.
Opportunities
- Higher Adoption of Synthetic API
The API process may involve multi-step drug synthesis and fermentation, crystallization, drying, packing, purification, milling, labelling, and testing. Some drugs that have been treated with an API may be bulk-finished products. Furthermore, because of safety concerns, active pharmaceutical ingredients in paediatric formulations have gotten a lot of attention from regulatory agencies all over the world. Small molecule drugs are currently gaining popularity in many drug pipelines. Small molecule drugs have received the most regulatory approvals, and this trend is expected to continue in the future. This factor is accelerating market growth.
Restraints/Challenges
- Unavailability of Appropriate Treatments
The high capital requirement for API production is due to the process's need for extremely systematic protocols, which results in the outsourcing of various APIs. It is unaffordable for low and middle-income countries.
This active pharmaceutical ingredients (API) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the active pharmaceutical ingredients (API) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Active Pharmaceutical Ingredients (API) Market
The COVID-19 pandemic has a substantial impact on the market for APIs worldwide. Several scientists created a list of drugs that target COVID-19. There are now 45 molecules in preclinical development and about 155 drugs in clinical trials that are working to protect COVID-19. Due to COVID-19's interruption of the supply chain, the API market witnessed significant changes. Geopolitical factors and the growing desire to lessen reliance on China for various API products have made nations like India preferred over China for exporting API.
Recent Developments
- In 2020, AbbVie Inc. acquired Allergan, a global company focused on manufacturing products for neuroscience, urology, and other medical fields. This acquisition enabled the company to expand its therapeutic categories and strengthen its financial values, accelerating the company's research and development activities.
- In 2019, AbbVie Inc. partnered with Scripps Research to accelerate research for new drug discovery targeting a variety of diseases, including oncology and immunology, among others. According to the collaboration agreement, Scripps Research will conduct pre-clinical research for the development of novel therapies. This collaboration aided the company in developing novel medicines for patients, which increased the company's revenue.
Europe Active Pharmaceutical Ingredients (API) Market Scope
The active pharmaceutical ingredients (API) market is segmented on the basis of molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Molecule
- Small Molecule
- Large Molecule
Type
- Innovative
- Generic Innovative
Type of Manufacturer
- Captive API Manufacturer
- Merchant API Manufacturer
Synthesis
- Synthetic
- Biotech
Chemical Synthesis
- Acetaminophen
- Artemisinin
- Saxagliptin
- Sodium Chloride
- Ibuprofen
- Losartan Potassium
- Enoxaparin Sodium
- Rufinamide
- Naproxen
- Tamoxifen
- Others
Type of Drug
- Prescription Drugs
- Over-the-Counter
Usage
- Clinical
- Research
Potency
- Low-to-Moderate Potency
- Potent-to-Highly Potent
Therapeutic Application
- Cardiology
- CNS and Neurology
- Oncology
- Orthopedic
- Endocrinology
- Pulmonology
- Gastroenterology
- Nephrology
- Ophthalmology
- Other Therapeutic Application
Active Pharmaceutical Ingredients (API) Market Regional Analysis/Insights
The active pharmaceutical ingredients (API) market is analyzed and market size insights and trends are provided by country, molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application as referenced above.
The countries covered in the active pharmaceutical ingredients (API) market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Germany is dominating in the Europe active pharmaceutical ingredients (API) market due to a rise in the demand for active medicinal compounds in consumer goods.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Active Pharmaceutical Ingredients (API) Market Share Analysis
The active pharmaceutical ingredients (API) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to active pharmaceutical ingredients (API) market.
Some of the major players operating in the active pharmaceutical ingredients (API) market are:
- Novartis AG (Switzerland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bausch Health Companies Inc. (Canada)
- UCB S.A. (Belgium)
- Sunovion Pharmaceuticals Inc. (U.S.)
- Jazz Pharmaceuticals, Inc. (U.K.)
- AstraZeneca (U.K.)
- GSK plc (U.K.)
- H. Lundbeck A/S (Denmark)
- Takeda Pharmaceutical Company Limited (Japan)
- Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Cadila Pharmaceuticals (India)
SKU-